Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Sunnybrook Health Sciences Centre
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07454707CT.gov Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial | — | Not Yet Recruiting | — | — | — |
NCT06900725CT.gov Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke | — | Not Yet Recruiting | — | — | — |
NCT06144866CT.gov Evaluataion of NOAC Levels in Acute Stroke | — | Unknown | — | — | — |
NCT03961334CT.gov MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention | — | Unknown | — | — | — |
NCT04010955CT.gov Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON) | — | Active Not Recruiting | — | — | — |
NCT03433235CT.gov Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation | — | Completed | — | — | — |
NCT03494530CT.gov Lixiana Acute Stroke Evaluation Registry | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edoxaban (this asset) | Sunnybrook Health Sciences Centre | Approved | BB · 70 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Clopidogrel | Nanfang Hospital, Southern Medical University | P4 | BB |
| Prednisolone | University of California, San Francisco | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Edoxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | A · 83 |
| Intracerebral Hemorrhage | — | P4 | BBB · 78 |
| Atrial Flutter | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Edoxaban in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/edoxaban-ischemic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →